Biolife Solutions Inc (BLFS) Stock Price & Analysis
Biolife Solutions Inc (BLFS) fell 2.57% to USD 29.98 as of July 25, 2026 at 10:39 UTC, according to Nexqual real-time market data.
BLFS last closed at USD 30.77; the session ranged USD 29.93–30.7 on volume of 2,599,275 shares. Market capitalization is $1.46B, with a 52-week range of USD 17.86–32.23 (NCM). Source: Nexqual, July 25, 2026 at 10:39 UTC.
Key Statistics (as of July 25, 2026 at 10:39 UTC)
| Price | USD 29.98 |
|---|---|
| Change | ▼ 2.57% (down) |
| Previous Close | USD 30.77 |
| Open | USD 30.44 |
| Day Range | USD 29.93 – 30.7 |
| 52-Week Range | USD 17.86 – 32.23 |
| Volume | 2,599,275 shares |
| Market Cap | $1.46B |
| Exchange | NCM |
Technical Analysis (BLFS)
Nexqual's technical model rates BLFS "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 10:39 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.31 (neutral) |
| vs SMA50 | Above (USD 26.64) |
| MACD | 1.07 (positive) |
Analyst Ratings (BLFS)
Wall Street analysts rate BLFS "Buy" based on 8 analysts, with a mean price target of USD 31.25 (range USD 30–33), per Nexqual as of July 25, 2026 at 10:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 31.25 |
| High Target | USD 33 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 3 / 6 / 0 |
Earnings (BLFS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.06 |
| Revenue Estimate | $28.17M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.04 vs est 0.02 ▲ beat |
| 2025-12-31 | USD 0.04 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.04 vs est 0 ▲ beat |
| 2025-06-30 | USD 0.01 vs est -0.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Financials & Fundamentals (BLFS)
| Total Revenue | $101.66M |
|---|---|
| Revenue Growth (YoY) | +24.70% |
| Gross Margin | +63.76% |
| Operating Margin | +0.10% |
| Profit Margin | -2.91% |
| ROE | -3.09% |
| Debt / Equity | 3.99 |
| Current Ratio | 7.3 |
| Total Cash | $81.00M |
| Total Debt | $14.86M |
| Free Cash Flow | $6.39M |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Financial Health Score (BLFS)
Nexqual rates Biolife Solutions Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 10:39 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 0% |
| Balance Sheet | Strong — $81M cash vs $15M debt, net cash position |
| Cash Flow | Solid — FCF $6M, 7% margin |
| Efficiency | Critical — ROE -3%, ROA -0.1% |
Ownership (BLFS)
| Insider Ownership | +2.37% |
|---|---|
| Institutional Ownership | +103.97% |
| Shares Outstanding | 48.86M |
| Float | 42.68M |
| Short % of Float | +9.15% |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Leadership (BLFS)
Biolife Solutions Inc is led by Roderick de Greef (age 65), CEO & Chairman, per Nexqual as of July 25, 2026 at 10:39 UTC.
| CEO & Chairman | Roderick de Greef (age 65) |
|---|---|
| Chief Technology Officer | Sean Werner (age 51) |
| Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Aby J. Mathew (age 53) |
Major Backers & Investors (BLFS)
Notable institutional backers of Biolife Solutions Inc include T. Rowe Price, Casdin Capital, LLC, Invesco, according to Nexqual as of July 25, 2026 at 10:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 21.36% |
| Casdin Capital, LLC | 12.19% |
| Invesco | 4.81% |
| FMR, LLC | 3.01% |
| -Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.49% |
| Massachusetts Financial Services Co. | 2.45% |
| Fred Alger Management, LLC | 2.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 19.37% |
| Vanguard Group | 6.87% |
| State Street | 3.23% |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
From Biolife Solutions Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
- The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
- The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.
- It markets and sells its products directly, as well as through third party distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYRX | CryoPort, Inc. | USD 15.37 | ▼ 6.39% |
| AXGN | AxoGen, Inc. | USD 39.49 | ▲ 0.3% |
| VCEL | Vericel Corporation | USD 45.05 | ▲ 1.1% |
| CDNA | CareDx, Inc. | USD 37.14 | ▼ 1.69% |
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:39 UTC. This page is informational and not investment advice.